ImmunoMet Therapeutics Announces the Formation of Scientific Advisory Board > Investors & Media

본문 바로가기

Investors & Media

ImmunoMet Therapeutics Announces the Formation of Scientific Advisory Board

Date :
March 10, 2016


ImmunoMet Therapeutics Announces the Formation of Scientific Advisory Board

Highly-Regarded Experts Have Extensive Experience in Cancer CelI and Immune Cell Metabolism


Houston, TX/USA, Daejeon, ROK, March 10, 2016 – ImmunoMet Therapeutics, a biotechnology company

developing innovative drugs for the treatment of cancer, today announced the formation of its Scientific

Advisory Board (SAB) that will provide valuable insight and strategic advice to the Company.


The SAB, comprised of renowned key opinion leaders in the areas of cancer cell and immune cell metabolism,

includes: Michael Pollak, M.D., Professor, Department of Oncology and Medicine, McGill University and Jewish

General Hospital, Montreal, CAN, who will serve as Chairman of the SAB; Gordon Mills, M.D., Ph.D.,

Department Chair, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD

Anderson Cancer Center, Houston, TX; Erika Pearce, Ph.D., Director, Immunology and Epigenetics, Max Planck

Institute, Freiburg, Germany; Russell Jones, Ph.D., Assistant Professor, Department of Physiology, Goodman

Cancer Research Center, McGill University, Montreal, CAN; Jae-Ho Cheong, M.D., Ph.D., Associate Professor,

Department of Surgery, Yonsei University, Seoul, Korea; and Seok-Gu Kang, M.D., PhD., Associate Professor,

Department of Neurosurgery, Yonsei University, Seoul, Korea.


Sung-wuk Kim, CEO of ImmunoMet Therapeutics, said, “We are pleased to welcome this prestigious group of

worldwide experts in the areas of immune cell metabolism and immuno-oncology to our SAB. Our

management team looks forward to working closely with this distinguished group, as we continue to move

forward with our innovative technology platforms that are focused on providing novel therapies that will

benefit cancer patients.”


At the Keystone Symposia on Molecular and Cellular Biology in Banff, Canada, members of the SAB and

ImmunoMet management team held its first annual SAB meeting and discussed the next steps to advance the

Company’s development programs. Abstracts presented by members of the SAB at Keystone Symposia

included: Russell Jones PhD., LKB, Links between Inflammation and Tumor Development; Erika Pearce
Metabolic Pathways in Effector and Memory T-cells; Michael Pollak M.D., Targeting Cancer Metabolism

with Metformin and Other Biguanides: from Bench to Bedsides and Back.


Michael Pollak M.D., said, “At McGill University, we are moving forward with laboratory studies of the

Company’s lead candidate, IM156, with currently-used drugs to improve their efficacy to treat cancers. The

data from these studies will be used to guide the design of the Phase 2 clinical trials, following the Phase 1

evaluation planned for later this year.”


About ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company, focused on the development of

innovative oncology products to improve the quality of life and make a meaningful difference in the lives of

cancer patients. The Company, a spinoff of HanAll Biopharma, has the extensive research and development

experience of HanAll’s scientists in the areas of immune cell metabolism and immuno-oncology, which address

the high unmet medical need to treat drug resistant and relapse cancers. The Company’s novel technology is

designed to disrupt cancer cell growth and enhance anti-cancer immunity and may be used in a broad range of

difficult-to-treat cancers. The Company’s lead compound, IM156, for the treatment of glioblastoma (brain

cancer) is expected to enter Phase 1 clinical development in the second half of 2016. For additional

information about the Company, please visit




Sanghee Yoo: 

Joseph T. Schepers: 919-616-1923, 


Copyright © ImmunoMet. All rights reserved.